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Thymic malignancies are rare epithelial tumors that may beaggressive and difficult to treat.1 Thymomas are usually
localized to the anterior mediastinum and are frequently
eligible for upfront surgical resection, which is the mainstay
of the curative-intent treatment.1 However, approximately
30% of patients present with an advanced tumor at the time
of diagnosis, with invasion of neighboring organs, dissemi-
nation to the pleura, the pericardium, or less frequently
extrathoracic organs. In such cases, chemotherapy has been
used both to reduce the tumor burden—possibly allowing
subsequent surgery or radiotherapy—and to achieve pro-
longed disease control. Recurrence after resection may be
similarly treated with chemotherapy. Thymic carcinomas,
although rare, are usually already advanced at the time of
presentation, and systemic therapy is important for almost all
of these patients.
Knowledge regarding chemotherapy for thymic tumors
has mainly been based on retrospective series,2–9 although
several prospective trials have also been conducted.10–21
These studies have clearly demonstrated the chemosensitivity
of thymoma, and to a lesser extent thymic carcinoma, to
various cytotoxic agents and combinations. However, details
of patient selection are often lacking (either disease extent or
general condition), and the intent of the treatment sequence is
often vague.
Adoption of a common language and definition of
terms is crucial for the International Thymic Malignancies
Interest Group (ITMIG) effort to develop a international
prospective database of thymic tumors. The article by Huang
et al.22 provides definitions for survival and endpoints for
recurrences assessment and discusses how to measure re-
sponse to treatment. Herein, we discuss additional points with
regard to chemotherapy, including treatment sequence, gen-
eral modalities, and impact of corticosteroids.
METHODS
This article represents a broad consensus within the
ITMIG community, based on available underlying evi-
dence. A core workgroup assembled data for discussion
based on a literature review and formulated proposed
definitions for data elements (N.G., G.J.R., P.J.L., R.L.,
and H.W.). These proposals were discussed at the ITMIG
Definitions and Terminology workshop on November 16,
2010, which was supported by the International Associa-
tion for the Study of Lung Cancer. Subsequent review with
an extended workgroup including radiation oncologists led
to refinement of these definitions. The manuscript was
distributed to all ITMIG members for further comment,
and ultimately the refined article was approved and ad-
opted by ITMIG members.
CHEMOTHERAPY IN THYMIC MALIGNANCIES
Intent of Treatment
Chemotherapy is used in various clinical scenarios for
thymic malignancies (Table 1). First, chemotherapy may
constitute part of curative-intent treatment for locally ad-
vanced tumors. The objective of the treatment strategy is to
achieve long-term survival with no evidence of recurrence. In
this setting, chemotherapy is combined with local treatment
(e.g., preoperative and postoperative chemotherapy and sur-
gery, or chemoradiotherapy).
Chemotherapy may also be delivered as palliative-
intent treatment in advanced or metastatic thymic tumors to
improve tumor-related symptoms. Despite a reasonable hope
for prolonged disease control, eradication of the tumor is not
expected. In this setting, chemotherapy is typically delivered
as the sole treatment modality.
The response and survival rates may significantly differ
depending on the clinical context for which chemotherapy is
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delivered. Our first recommendation is that before beginning
chemotherapy, the intent of treatment is clearly stated
(Table 1; Figure 1): (1) is chemotherapy delivered as
curative or palliative-intent treatment? (2) For curative-
intent primary chemotherapy, is subsequent surgery or
radiotherapy or both planned? Obviously the final treat-
ment strategy may change depending on tumor response
and other criteria. Investigators should indicate which
treatments the patient ultimately received. A prospective
database with such information will allow meaningful
integration of reports from different institutions.
The wide variation in the number of patients treated
with surgery or radiotherapy after primary chemotherapy
suggests significant heterogeneity in the inclusion criteria
FIGURE 1. Summary and defini-
tions of treatment strategies involv-
ing chemotherapy in thymic malig-
nancies.
TABLE 1. Summary of Reporting Guidelines and Data Fields for Thymic Malignancies Treated with Chemotherapy
Chemotherapy strategies
Initial treatment
Curative intent
Primary chemotherapy Chemotherapy delivered before another focal treatment—surgery or radiotherapy.
Intent of the treatment has to be documented, i.e., primary chemotherapy before surgery or
primary chemotherapy before radiotherapy.
Final strategy has to be indicated for all patients: primary preoperative chemotherapy or
primary chemoradiotherapy.
Postoperative chemotherapy Chemotherapy delivered after surgery.
Completeness of the resection (R0, R1, or R2) should be indicated.
Palliative intent
Palliative chemotherapy Chemotherapy delivered alone in cases for which there is no plan for surgery or radiotherapy.
Chemotherapy for recurrence Chemotherapy delivered for tumor recurrence appearing after previous curative-intent treatment.
Chemotherapy for recurrence may be curative intent (primary preoperative/chemoradiation,
postoperative) or palliative intent (chemotherapy alone).
Intent of the treatment and final strategy have to be documented as for initial treatment.
Chemotherapy general reporting guidelines
Modalities Chemotherapy regimen
Number of cycles administered
Dose intensity:  or 70% of the planned dose intensity
Analysis Treatment outcome has to be evaluated separately for thymoma and thymic carcinoma.
Toxicities Grade 3–5 and dose-limiting toxicities (acute and late) of the treatment may be reported using
the National Cancer Institute Common Terminology Criteria for Adverse Events v4 system.
Acute and late toxicities have to be reported. Special attention has to be paid to late and
chronic toxicities of the treatment, such as cardiac toxicities.
Response Assessment of tumor response has been described in a previous article.22
Octreoscan results should be reported for patients treated with octreotide.
Effect of antitumor treatment on associated paraneoplastic manifestations has to be documented.
Corticosteroid treatment doses (equivalent prednisone doses above 0.5 mg/kg/d) and durations
should be reported.
Recurrence Rebound hyperplasia has to be considered as a differential diagnosis for local recurrence when
tumor regrowth occurs within the 15 months after treatment cessation.
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among studies (Table 2). This highlights the need to clearly
state the inclusion criteria, the treatment intent and plan, and
the treatment that was eventually delivered.
General Reporting Guidelines for
Chemotherapy
When reporting on primary, postoperative, and pal-
liative chemotherapy, investigators should clearly indicate:
(1) the cytotoxic agents used, (2) the number of cycles, and
(3) whether more than 70% of the planned dose intensity
was eventually delivered.23 This threshold is usually cho-
sen in chemotherapy phase II trials to define the feasibility
of a proposed treatment.
Acute and late toxicity of chemotherapy should be
carefully and systematically evaluated according to the Na-
tional Cancer Institute Common Terminology Criteria for
Adverse Events v4 system.24 Grade 3 to 5 and dose-limiting
toxicities should be documented. Investigators should pay
special attention to the accurate assessment of late and
chronic toxicities, because patients with thymoma live longer
than patients with other types of cancers. In particular, there
may be an underestimated increased risk of cardiac toxicity
because of repeated use of anthracyclines, often combined
with radiotherapy and surgery, and possibly development of
paraneoplastic myocarditis.25
Response assessment recommendations for thymic
malignancies are described in a previous ITMIG article.22
The results for thymoma and thymic carcinoma should be
reported separately. The main imaging study used for
tumor response assessment is computed tomography (CT)
scan. In patients receiving octreotide, octreoscan results
should be documented before therapy.26 We also recom-
mend systematic documentation of the effect of antitumor
treatment on associated paraneoplastic syndromes (if pres-
ent),27 which should include documentation of any con-
current specific therapies (e.g., symptom-palliation or im-
munosuppressive drugs).
Curative-Intent Chemotherapy
Curative-intent chemotherapy may be delivered either
before surgery or radiotherapy (primary chemotherapy), con-
current with radiotherapy, or after surgery (postoperative
chemotherapy; Table 1, Figure 1).
Primary Chemotherapy
Primary chemotherapy is a chemotherapy delivered as
first treatment in case of locally advanced nonmetastatic
thymic tumor (Masaoka-Koga stage III or IVA28). The che-
mosensitivity of thymoma provides a strong rationale to use
chemotherapy in this setting. The main objective of primary
chemotherapy is to make feasible subsequent R0 resection,
which is the most significant prognostic factor on survival in
thymic malignancies.29
Several chemotherapy regimens have been used in
this setting (Table 2). Usually two to four cycles of
primary chemotherapy are administered. Imaging reassess-
ment with contrast-enhanced CT scan is usually performed
3 to 4 weeks after the last chemotherapy injection. If
surgical resection is the objective of the therapeutic strat-
egy for locally advanced thymic tumors, the final treatment
plan may change depending on tumor response to primary
chemotherapy (Figure 1). A response is observed in ap-
proximately 70 to 80% of cases in the largest studies
(Table 2). Patients for whom R0 resection is thought to be
TABLE 2. Primary Chemotherapy or Chemoradiation for Locally Advanced Thymic Malignancies
Reference
Primary
Chemotherapy
Regimen n
Period of
Accrual
(yr)
Tumor
Study
Response
Rate (%)
Subsequent Treatment (%)
Type Stage Surgery
Complete
Resection
RT (Definitive
ChemoRT)
Palliative
Chemo-
therapy
Chemotherapy
Macchiarini14 CEE 7 2 T/TC III Phase II 100 100 57 0 0
Berruti16 ADOC 6 2 T III-IVA Phase II 83 ? 17 ? ?
Rea6 ADOC 16 6 T III-IVA Retrospective 100 100 69 0 0
Venuta3 CEE 15 14 T/TC III Retrospective 66 100 ? ? ?
Bretti7 ADOC/PE 25 11 T/TC III-IVA Retrospective 72 68 44 ? ?
Kim15 CAPP 22 10 T Phase II 77 100 72 0 0
Lucchi4 CEE 36 27 T/TC III-IVA Retrospective 67 69 78 19 3
Jacot5 CAP 5 6 T/TC III-IVA Retrospective 75 38 25 50 12
Yokoi8 CAMP 14 15 T/TC III, IVA-B Retrospective 93 64 14 14 21
Kunitoh17 CODE 21 8 T III Phase II 62 62 43 24 14
Chemoradiation
Loehrer18 CAP 23 12 T/TC III-IVA phase II 70 15 0 70 15
Berruti19 ADOC 16 7 T III-IVA phase II 81 56 56 31 13
Wright9 PE, ADOC, CAP,
CEE
10 9 T/TC III-IVA Retrospective 40 100 80 0 0
The CAP, ADOC, and PE regimen are described in Table 1. The CODE regimen consists of cisplatin (25 mg/m2/wk), vincristin (1 mg/m2/wk), adriamycin (40 mg/m2/wk), and
etoposide (80 mg/m23 d/wk), the CEE regimen of cisplatin (75 mg/m2/3 wk), epirubicin (100 mg/m2/3 wk), etoposide (120 mg/m23 d/ 3 wk), and the CAMP regimen of CAP
with prednisolone (1000 mg/m24 d and 500 mg/m22 d/3 wk).
T, thymoma; TC, thymic carcinoma; RT, radiotherapy.
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feasible undergo surgery. A time interval longer than 8
weeks between the last cycle of chemotherapy and surgery is
not considered appropriate. In the largest reported series,
surgery was performed in the majority of patients, and com-
plete resection was achieved in approximately 50% of cases.
For those cases, the final treatment strategy is “primary
preoperative chemotherapy followed by surgery.”
When the patient is not deemed to be a surgical candi-
date—either because R0 resection is not believed to be
achievable or because of poor performance status or coexis-
tent medical condition (“medically inoperable” patient)—
curative-intent, definitive radiotherapy may be delivered
(Figure 1).30 The curative value of radiotherapy in this setting
has to be evaluated in further studies. In the literature,
radiotherapy is ultimately delivered in 0 to 50% of patients
receiving primary chemotherapy (Table 2). The final treat-
ment strategy is “definitive chemoradiotherapy.” A time in-
terval longer than 6 weeks between the last chemotherapy
cycle and the delivery of the first radiation fraction is not
considered appropriate. Chemotherapy may be given concur-
rently with the radiation therapy.
If radiotherapy is not feasible, either because of a large
tumor burden that precludes safe delivery of appropriate
doses or because of comorbidities increasing the risks of
radiation-induced toxicity, treatment consists of chemother-
apy alone. Treatment with chemotherapy alone is a strategy
that is ultimately palliative (Figure 1, see below). In the
reported literature, 0 to 21% of patients with locally advanced
thymic tumors receiving primary chemotherapy cannot re-
ceive surgery or radiation therapy or other local treatment
(Table 2). The final treatment strategy is “palliative chemo-
therapy” (see below).
Our recommendations for reporting on curative-in-
tent chemotherapy for locally advanced thymic tumors are
the following (Table 1): (1) the terms “induction chemo-
therapy” and “neoadjuvant chemotherapy” should be re-
placed by the term “primary chemotherapy”; (2) the terms
“marginally resectable,” “potentially respectable,” and
“unresectable” tumors should be avoided; instead, inves-
tigators should indicate tumor stage28; (3) intent of primary
chemotherapy, that is, before surgery or radiotherapy; and
(4) final treatment strategy have to be detailed for all
patients: preoperative chemotherapy followed by surgery,
definitive chemoradiotherapy, or palliative chemotherapy;
and (5) thymomas and thymic carcinomas should be ana-
lyzed separately. Of note, some series including patients
with locally advanced thymic tumors reported on the use of
primary chemotherapy associated with sequential or con-
current radiotherapy in a preoperative intent (Table 2).
Such strategy should be referred to as “preoperative che-
moradiotherapy.”
Postoperative Chemotherapy
Postoperative chemotherapy is defined as a chemother-
apy delivered after surgery (Table 1). Only sparse evidence
exists in the literature regarding postoperative chemotherapy
in thymic malignancies. The rationale is limited in thymomas
given the low incidence of systemic recurrences after defin-
itive surgery.29 Adjuvant chemotherapy regimens are similar
to those of primary chemotherapy. Postoperative chemother-
apy consisted of cyclophosphamide, doxorubicin, cisplatin in
a French series of 21 stage III-IVA thymoma patients,31 and
cyclophosphamide, doxorubicin, and cisplatin plus predni-
sone were used in two prospective MD Anderson Cancer
Center trials of postoperative radiotherapy followed by che-
motherapy.15,32 Current guidelines do not recommend the use
of postoperative chemotherapy in thymoma.
However, thymic carcinomas often exhibit frequent and
early locoregional and systemic recurrences after surgery.33
In a large series that included 92 thymic carcinomas, 5-year
survival was 82% with postoperative chemotherapy (n 12),
47% with postoperative chemoradiation (n  24), 74% with
postoperative radiotherapy (n  33), and 72% with no post-
operative treatment (n  16).29 However, the number of
patients is small, and they were selected for a particular
treatment approach, highlighting the need for collaborative,
well-defined research.
Our recommendations for reporting on postoperative
chemotherapy for thymic malignancies are as follows: (1) use
the term “postoperative chemotherapy” instead of “adjuvant
chemotherapy” or “consolidation chemotherapy”; it is
self-explanatory and is consistent with reporting guidelines
for radiotherapy30; (2) thymomas and thymic carcinomas
should be analyzed separately; and (3) the completeness of
the resection should be indicated (i.e., complete resection
[R0], microscopic residual disease [R1], or gross residual
disease [R2]).
Chemotherapy after R2 resection is considered as post-
operative chemotherapy, provided surgery is performed with
curative intent (not simply for diagnosis)—this definition
maintains consistency with that recommended for postoper-
ative radiotherapy.30 After an R2 resection, postoperative
radiotherapy may be combined sequentially or concurrently
with chemotherapy (this latter instance is referred to as
postoperative chemoradiotherapy).
Postoperative chemotherapy should be initiated within
12 weeks after surgery. The term postoperative chemotherapy
is still appropriate after more than 12 weeks when both
chemotherapy and radiotherapy are planned, and the radio-
therapy was initiated within 12 weeks, provided no tumor
recurrence is observed. Chemotherapy that is initiated post-
operatively because imaging reveals recurrence or progres-
sion of disease should be labeled as “chemotherapy for
recurrent disease” not postoperative chemotherapy.
Palliative-Intent Chemotherapy
Palliative Chemotherapy
Palliative chemotherapy is given as the sole treatment
modality, with no plan for surgery or radiotherapy, for ex-
ample, in patients with metastatic disease (Table 1). Palliative
chemotherapy may also ultimately be the treatment given in
patients with locally advanced tumors which do not respond
sufficiently to be eligible for subsequent surgery or radiother-
apy (Figure 1). The objectives of palliative-intent chemother-
apy are to improve potential tumor-related symptoms and to
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achieve tumor response. Prolonged disease control is possi-
ble, but tumor eradication is not expected.
Several prospective and retrospective studies have re-
ported on palliative chemotherapy regimens (Table 3), but
because there are no randomized studies, it is unclear which
regimen is best; however, anthracycline-based regimens seem
to have improved response rates. In general, a combination
regimen is recommended, for at least three and no more than
six cycles.
In the palliative-intent setting, several consecutive lines
of chemotherapy may be administered when the patient
presents with tumor progression. We recommend the use of
the standard terms “first-line,” “second-line,” and “third-line”
chemotherapy, etc.
Chemotherapy for Recurrence
Chemotherapy for recurrence refers to chemotherapy
delivered for tumor recurrence appearing after previous cu-
rative-intent treatment, which results in complete disappear-
ance of tumor. This term should not be used for tumor
progression after palliative-intent chemotherapy without a
complete response. In this scenario, chemotherapy is referred
to as second-line or third-line chemotherapy.
Similar to what is done for initial management, the
treatment of thymic tumor recurrences are typically palliative
intent but may be curative intent; in this latter situation,
treatment may include chemotherapy, surgery, or radiother-
apy. As for radiotherapy, our recommendation is to use the
same terms and policies as for initial treatment, but stating
that this is for recurrence.
CORTICOSTEROIDS IN THYMIC
MALIGNANCIES
Impact on Response Assessment
Corticosteroids have been known for a long time to
have a “lympholytic” effect.35,36 The thymuses of patients
receiving corticosteroids have significantly increased fat and
connective tissue, decreased germinal centers, and resulted in
poorer corticomedullary differentiation than those of un-
treated patients not receiving steroids. The changes after
corticosteroid treatment mimic those after aging or acute
stress, with retention of the myoepithelial stroma but deple-
tion of thymic lymphoid elements. In lymphocytic thymomas
(type AB, B1, and B2), corticosteroids may then produce a
significant reduction of lesion size at imaging studies through
lymphocytic depletion, with no antitumor effect.
Only limited data are available regarding the signifi-
cance of this phenomenon in a clinical setting. In the Eastern
Cooperative Oncology Group phase II trial evaluating the
combination of octreotide and corticosteroids (prednisone at a
dose of 0.6 mg/kg/d) versus octreotide alone, higher response
rates were observed in patients receiving corticosteroids (38
versus 11% in patients treated with octreotide alone).26
Given the possible impact of corticosteroids on re-
sponse assessment, our recommendation is to document
whether the patient has received corticosteroids at a dose
higher than 0.5 mg/kg/d of prednisone (or a correspondingly
equivalent dose of another steroid) and the duration of cor-
ticosteroids treatment. The 0.5 mg/kg/d cutoff is chosen
based on the dose delivered in the Eastern Cooperative
Oncology Group trial and to avoid complex reporting of
TABLE 3. Palliative Chemotherapy Regimens in Advanced Thymic Malignancies
Reference n
Period of
Accrual
(years)
Tumor
Type Study Regimen Agents Doses
Response
Rate (%)
Single-agent chemotherapy
Bonomi et al.20 21 4 T/TC Phase II Cisplatin 50 mg/m2/3 wk 10–62
Highley et al.21 15 12 T/TC Retrospective Ifosfamide 1.5 g/m25 d/3 wk 46–54
Loehrer et al.34 27 1 T/TC Phase II Pemetrexed 500 mg/m2/3 wk 17
Combination chemotherapy
Fornasiero et al.2 32 11 T Retrospective ADOC Adriamycin 40 mg/m2/3 wk 85–92
Cisplatin 50 mg/m2/3 wk
Vincristin 0.6 mg/m2/3 wk
Cyclophosphamide 700 mg/m2/3 wk
Loehrer et al.10 30 9 T/TC Phase II CAP Cisplatin 50 mg/m2/3 wk 51
Adriamycin 50 mg/m2/3 wk
Cyclophosphamide 500 mg/m2/3 wk
Giaccone et al.11 16 6 T Phase II PE Cisplatin 60 mg/m2/3 wk 56–60
Etoposide 120 mg/m23/3 wk
Loehrer et al.12 34 2 T/TC Phase II VIP Etoposide 75 mg/m24 d/3 wk 32
Ifosfamide 1.2 g/m24 d/3 wk
Cisplatin 20 mg/m24 d/3 wk
Lemma et al.13 46 7 T/TC Phase II Carbo-Px Carboplatin Area under the curve 5/3 wk 33
Paclitaxel 225 mg/m2/3 wk
T, thymoma; TC, thymic carcinoma.
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temporary administration of corticosteroids at low doses to
control chemotherapy side effects. We recommend that re-
sponse rates be reported and analyzed separately for patients
receiving or not receiving steroids at this dose or higher.
Ultimately, whether response criteria should be modified for
thymomas with a substantial lymphocytic component versus
other thymic malignancies when corticosteroids are given is
currently unknown and calls for prospective studies.
Impact on Definition of
Recurrence/Progression
The thymus may enlarge in various circumstances,
including infections, burns, and corticosteroid or chemother-
apy cessation (especially after an intensive regimen given to
infants and young adults).37–39 This phenomenon is referred
as “rebound thymic hyperplasia.” Rebound hyperplasia has
been reported to occur 2 to 14 months after cessation of
corticosteroids and may persist for 2 to 45 months. Histolog-
ically, it corresponds to a true thymic hyperplasia, with
enlargement of the thymus, and no increase in the number of
lymphoid follicles.40
Rebound hyperplasia has not been reported to occur
in patients with thymic tumors but needs to be discussed
given the potential implication on outcome assessment.
Given the reported timeframe of this phenomenon, our
recommendation is to consider rebound hyperplasia as in
patients presenting with a potential local recurrence who
stopped chemotherapy or corticosteroids within 15 months
of regrowth of the thymic lesion.
Certain imaging characteristics may help to distinguish
thymic hyperplasia and tumor recurrence. Typically, thymic
hyperplasia results in a symmetric, nonfocal enlargement of
the thymus on a CT scan. Both thymic hyperplasia and
thymoma may be intimately related to the vessels (without
invasion).40 Fluorodeoxyglucose positron emission tomogra-
phy is not useful in this setting because both entities exhibit
similar degrees of increased fluorodeoxyglucose uptake.41
Chemical shift magnetic resonance imaging has also been
evaluated to distinguish thymoma and thymic hyperplasia.42
If the nature of thymic enlargement occurring within 15
months of treatment cessation is unclear based on imaging
tissue, biopsy is recommended.
DISCUSSION
Chemotherapy is a major treatment modality for thy-
moma and thymic carcinoma. This article defines terms and
policies, so that outcomes after chemotherapy can be reported
in a consistent manner. These measures represent a consensus
of the ITMIG community and will be used in ITMIG collab-
orative projects. Adopting these definitions will allow ITMIG
members and others interested in the field to compare results
and conduct collaborative investigations. The definitions may
be updated in the future as new information comes to light.
For example, the curative value of surgery or radiotherapy in
specific clinical settings, such as stage IVA disease, should be
evaluated in further studies.
A major impediment to progress is the limited number
of patients in studies to date (Tables 1 and 2). The ITMIG
prospective international database together with consistently
defined terms will allow analysis of much larger patient
cohorts over shorter period of time. Many questions regard-
ing chemotherapy for thymic malignancies remain unan-
swered; however, the consistency afforded by the consensus
definitions in this article and the collaborative spirit of ITMIG
provide a framework, so that they can be addressed.
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